PENTOSAN POLYSULFATE AS PROPHYLAXIS FOR MIGRAINE

戊聚糖多硫酸预防偏头痛

• 批准号: 3860005
• 负责人: L B BIGELOW
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3860005
• 关键词: basophils; blood cell count; brain disorder chemotherapy; disease /disorder prevention /control; headache; human subject; human therapy evaluation; migraine; pentosan; sulfates

Pentosan polysulfate (PPS), a semi-synthetic polyanion, has been under investigation here for a number of years as a prophylactic treatment for migraine and cluster headache. These pilot studies were all single blind. Results have been sufficiently encouraging to justify a double blind protocol to confirm or refute the clinical data. The main predictor of response has been a low circulating basophil count. A protocol has been approved which involves screening a population of migraineurs, selecting those with low basophil counts and randomizing them into a double blind placebo controlled study.

戊聚糖多硫酸酯（PPS）是一种半合成聚阴离子，已被研究 作为预防性治疗，这里进行了多年的调查 偏头痛和丛集性头痛。 这些试点研究都是单盲的。 结果足以令人鼓舞，证明双盲是合理的 确认或反驳临床数据的协议。 反应的主要预测因素是循环嗜碱性粒细胞计数低。 一项方案已获得批准，其中涉及筛查人群 偏头痛患者，选择嗜碱性粒细胞计数低的患者并将其随机化 进入双盲安慰剂对照研究。